# Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District

> **NCT03001570** · PHASE2 · UNKNOWN · sponsor: **European Institute of Oncology** · enrollment: 10 (estimated)

## Conditions studied

- Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Cetuximab plus Radiotherapy

## Key facts

- **NCT ID:** NCT03001570
- **Lead sponsor:** European Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-01
- **Primary completion:** 2018-12
- **Final completion:** 2023-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03001570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03001570, "Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03001570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*